Mimedx (MDXG) Net Cash Flow Growth (5y) (2016 - 2026)
Mimedx (MDXG) Net Cash Flow Growth (5y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,839.48 Bn | 65,839.20 Bn | - |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - |
| 3 | Akari Therapeutics | 1,015.37 Bn | 1,015.37 Bn | - |
| 4 | BeOne Medicines | 471.39 Bn | 466.59 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.52 Bn | 115.28 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.33 Bn | 61.58 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - |
| 8 | Argenx Se | 56.10 Bn | 50.91 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.52 Bn | 34.51 Bn | 959.66 Mn |
| 10 | Mimedx | 645.74 Mn | 485.97 Mn | 41.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.52% |
| Dec 31, 2025 | 30.22% |
| Sep 30, 2025 | -17.68% |
| Jun 30, 2025 | 34.07% |
| Mar 31, 2025 | 16.32% |
| Dec 31, 2024 | 21.27% |
| Sep 30, 2024 | 56.45% |
| Jun 30, 2024 | -21.41% |
| Mar 31, 2024 | -14.90% |
| Dec 31, 2023 | -166.31% |
| Sep 30, 2023 | 77.88% |
| Jun 30, 2023 | -8.25% |
| Mar 31, 2023 | 39.77% |
| Dec 31, 2022 | 20.43% |
| Sep 30, 2022 | 15.61% |
| Jun 30, 2022 | -16.99% |
| Mar 31, 2022 | -26.89% |
| Dec 31, 2021 | -22.92% |
| Sep 30, 2021 | 24.78% |
| Jun 30, 2021 | -50.39% |